Araştırma Makalesi

Clinicopathological Predictors of Pathologic Complete Response in Triple-Negative Breast Cancer: Impact of Platinum-Based Neoadjuvant Chemotherapy

Sayı: 1 24 Mart 2026
PDF İndir
EN TR

Clinicopathological Predictors of Pathologic Complete Response in Triple-Negative Breast Cancer: Impact of Platinum-Based Neoadjuvant Chemotherapy

Öz

Aim: This retrospective cohort study aimed to assess the association between platinum-based neoadjuvant chemotherapy and pathologic complete response (pCR) rates, and to identify predictors of pCR in women with triple-negative breast cancer (TNBC). Material and Methods: We retrospectively analyzed 219 women with histologically confirmed TNBC who received neoadjuvant chemotherapy at a single institution between 2015 and 2024. Clinicopathological data, including age, menopausal status, tumor grade, Ki-67 proliferation index, and treatment regimen (platinum-or non-platinum-based), were evaluated. Logistic regression analyses were performed to identify independent predictors of pCR, and Kaplan–Meier survival analysis was used to assess the association between pCR and survival. Results: The overall pCR rate was 26.5%. Patients receiving platinum-based chemotherapy achieved significantly higher pCR rates than those treated without platinum (33.0% vs. 20.4%, p = 0.034). In multivariate analysis, younger age at diagnosis and a higher Ki-67 proliferation index independently predicted pCR. Platinum-based chemotherapy and postmenopausal status demonstrated clinically relevant but statistically non-significant trends toward higher pCR rates. Achieving pCR was significantly associated with improved disease-free survival (DFS) (p < 0.001) and showed a favorable trend toward improved overall survival (OS) (p = 0.056). No significant differences in survival outcomes were observed according to platinum exposure alone. Conclusion: Kaplan-Meier analysis suggested that achieving pCR is important for disease-free survival and that there is a positive trend toward improved overall survival in patients with triple-negative breast cancer. Although platinum-based chemotherapy did not confer a clear survival advantage, its association with higher pCR rates supports its use in the neoadjuvant setting, particularly in selected patients with biologically aggressive disease. These findings reinforce the prognostic value of pCR and highlight the importance of tumor biology in guiding neoadjuvant treatment strategies in triple-negative breast cancer.

Anahtar Kelimeler

Destekleyen Kurum

No funding was received for this study.

Etik Beyan

This study was approved by the Institutional Ethics Committee (Approval No: 2025/374. Date: 07.11.2025). All procedures were conducted in accordance with the Declaration of Helsinki. As this was a retrospective study, the requirement for informed consent was waived by the committee.

Teşekkür

No acknowledgments.

Kaynakça

  1. Zagami P, Carey LA. Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer. 2022;8(1):95.
  2. Almansour NM. Triple-negative breast cancer: A brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence. Front Mol Biosci. 2022;9:836417.
  3. Adrada BE, Moseley TW, Kapoor MM, Scoggins ME, Patel MM, Perez F, et al. Triple-negative breast cancer: Histopathologic features, genomics, and treatment. Radiographics. 2023;43(10):e230034.
  4. Xiong N, Wu H, Yu Z. Advancements and challenges in triple-negative breast cancer: A comprehensive review of therapeutic and diagnostic strategies. Front Oncol. 2024;14:1405491.
  5. Matossian M, Chen N, Nanda R. Exploiting therapeutic vulnerabilities in triple-negative breast cancer: Successes, challenges, and opportunities. Curr Breast Cancer Rep. 2023;15(3):266-278.
  6. Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey S, et al. Evaluation of pathologic complete response as a surrogate for long-term survival outcomes in triple-negative breast cancer. J Natl Compr Canc Netw. 2020;18(8):1096-1104.
  7. RS R. Neoadjuvant chemotherapy in triple-negative breast cancer: Impact on early stage and outcomes-comprehensive review. Indian J Surg Oncol. 2024;15(Suppl 3):501-508.
  8. Toss A, Venturelli M, Civallero M, Piombino C, Domati F, Ficarra G, et al. Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy. Front Oncol. 2022;12:1016295.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Klinik Onkoloji

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

24 Mart 2026

Gönderilme Tarihi

22 Kasım 2025

Kabul Tarihi

30 Ocak 2026

Yayımlandığı Sayı

Yıl 2026 Sayı: 1

Kaynak Göster

APA
Özyurt, N., & Turhan, A. (2026). Clinicopathological Predictors of Pathologic Complete Response in Triple-Negative Breast Cancer: Impact of Platinum-Based Neoadjuvant Chemotherapy. Medical Records, 1. https://doi.org/10.37990/medr.1828536
AMA
1.Özyurt N, Turhan A. Clinicopathological Predictors of Pathologic Complete Response in Triple-Negative Breast Cancer: Impact of Platinum-Based Neoadjuvant Chemotherapy. Med Records. 2026;(1). doi:10.37990/medr.1828536
Chicago
Özyurt, Neslihan, ve Aykut Turhan. 2026. “Clinicopathological Predictors of Pathologic Complete Response in Triple-Negative Breast Cancer: Impact of Platinum-Based Neoadjuvant Chemotherapy”. Medical Records, sy 1. https://doi.org/10.37990/medr.1828536.
EndNote
Özyurt N, Turhan A (01 Mart 2026) Clinicopathological Predictors of Pathologic Complete Response in Triple-Negative Breast Cancer: Impact of Platinum-Based Neoadjuvant Chemotherapy. Medical Records 1
IEEE
[1]N. Özyurt ve A. Turhan, “Clinicopathological Predictors of Pathologic Complete Response in Triple-Negative Breast Cancer: Impact of Platinum-Based Neoadjuvant Chemotherapy”, Med Records, sy 1, Mar. 2026, doi: 10.37990/medr.1828536.
ISNAD
Özyurt, Neslihan - Turhan, Aykut. “Clinicopathological Predictors of Pathologic Complete Response in Triple-Negative Breast Cancer: Impact of Platinum-Based Neoadjuvant Chemotherapy”. Medical Records. 1 (01 Mart 2026). https://doi.org/10.37990/medr.1828536.
JAMA
1.Özyurt N, Turhan A. Clinicopathological Predictors of Pathologic Complete Response in Triple-Negative Breast Cancer: Impact of Platinum-Based Neoadjuvant Chemotherapy. Med Records. 2026. doi:10.37990/medr.1828536.
MLA
Özyurt, Neslihan, ve Aykut Turhan. “Clinicopathological Predictors of Pathologic Complete Response in Triple-Negative Breast Cancer: Impact of Platinum-Based Neoadjuvant Chemotherapy”. Medical Records, sy 1, Mart 2026, doi:10.37990/medr.1828536.
Vancouver
1.Neslihan Özyurt, Aykut Turhan. Clinicopathological Predictors of Pathologic Complete Response in Triple-Negative Breast Cancer: Impact of Platinum-Based Neoadjuvant Chemotherapy. Med Records. 01 Mart 2026;(1). doi:10.37990/medr.1828536